Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00417716
Verified June 2006 by Asociación para Evitar la Ceguera en México. Recruitment status was: Active, not recruiting
Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema
Condition or disease
Diabetes Mellitus Type 2Diabetic Macular Edema
Drug: Intravitreal Bevacizumab
A non-randomized prospective clinical interventional study which includes 45 non previously treated patients with DME. The patients received a single intravitreal injection of 2.5 mg bevacizumab. Follow-up included clinical examination (best corrected visual acuity (BCVA, intraocular pressure (IOP), cataract grading, DME characteristics and systemic check-up) pre-injection, at first visit, at weeks 1 and 2 and months 1 and 3. OCT and fluorescein angiography was evaluated at months 1 and 3.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
45 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Type 2 diabetes
Macular edema involving the center of the macula demonstrated on OCT
Clear ocular media
Older than 45 years
BCVA of the fellow eye at least 20/100
Renal diabetic disease, uncontrolled hypertension or stroke history
Other ocular disease
Ocular surgery excepting uncomplicated phacoemulsification
History of photocoagulation (panretinal or focal)
History of another intravitreal treatment (like triamcinolone)